August 14, 2023
4 min watch
Save
VIDEO: Consider drug holiday, switch from bisphosphonate for osteoporosis therapy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SANTA FE, N.M. — In this video exclusive, Michael R. McClung, MD, discusses strategies for drug holidays and transitions between osteoporosis therapies.
McClung is the founding director of the Oregon Osteoporosis Center in Portland.
Use of bisphosphonates has no incremental benefit after 5 years of therapy, McClung said, and at that time, prescribers should consider a drug holiday or a switch to therapy with denosumab (Prolia, Amgen) or an osteoanabolic agent.
McClung describes special concerns when discontinuing denosumab and reviews arguments for using an osteoanabolic agent as initial therapy.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
McClung reports speaking and consulting for AbbVie, Alexion, Amgen, Exeltis and UCB. He is a board member for the International Osteoporosis Foundation, the American Society of Osteoporosis Practitioners and the North American Menopause Society.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.